Breast Cancer
From the Journals
Gaps exist in receipt of clinically indicated genetic counseling after breast cancer diagnosis
Less than half of patients diagnosed with early breast cancer with an indication for genetic risk evaluation received formal genetic counseling....
Conference Coverage
CECCY: Carvedilol didn’t curb cardiotoxicity in breast cancer patients
ORLANDO – “In short follow up, we can see cardiotoxicity appearing, and we know we have to treat it promptly to prevent cardiac events.”
From the Journals
Age at time of breast cancer diagnosis differs by race/ethnicity
Age-based screening may not provide equal capture rates for whites, nonwhites.
From the Journals
Breast cancer care delayed when patients have high deductibles
Women with an employer-mandated switch from a low- to high-deductible health plan had significant delays in diagnostic imaging, biopsy, diagnosis...
News
FDA authorizes first direct-to-consumer BRCA1/2 test
The test identifies the three most common BRCA1/2 mutations among people of Ashkenazi Jewish descent.
News
FDA approves abemaciclib plus aromatase inhibitor as initial therapy
Abemaciclib plus an aromatase inhibitor was approved as initial endocrine-based therapy in women with HR-positive, HER2-negative metastatic breast...
Feature
Breast cancer deaths projected for 2018
The most common cancer in women is not the biggest killer.
Original Report
Measurement of physical activity and sedentary behavior in breast cancer survivors
Community Translations
Abemaciclib becomes first CDK inhibitor to clinch single-agent approval for breast cancer
Conference Coverage
Exercise during chemotherapy may yield long-term physical benefits
ORLANDO – Four years after participating in an 18-week exercise program during cancer treatment, patients reported more moderate-to-vigorous...
From the Journals
Cyclophosphamide extends PFS in elderly HER2+ breast cancer patients
Adding oral cyclophosphamide to trastuzumab and pertuzumab in frail elderly HER2-positive metastatic breast cancer patients improved median PFS by...